Monte Rosa Therapeutics Inc (NASDAQ: GLUE) kicked off on Tuesday, down -1.38% from the previous trading day, before settling in for the closing price of $5.07. Over the past 52 weeks, GLUE has traded in a range of $2.44-$8.84.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 27.69%. With a float of $44.59 million, this company’s outstanding shares have now reached $50.14 million.
Let’s look at the performance matrix of the company that is accounted for 133 employees. In terms of profitability, gross margin is 47.37%, operating margin of -960.79%, and the pretax margin is -895.4%.
Monte Rosa Therapeutics Inc (GLUE) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Monte Rosa Therapeutics Inc is 27.35%, while institutional ownership is 62.23%. The most recent insider transaction that took place on Sep 20 ’24, was worth 7,395,203. In this transaction 10% Owner of this company sold 1,132,566 shares at a rate of $6.53, taking the stock ownership to the 5,099,336 shares. Before that another transaction happened on Sep 11 ’24, when Company’s 10% Owner sold 541,897 for $6.00, making the entire transaction worth $3,251,382. This insider now owns 6,257,218 shares in total.
Monte Rosa Therapeutics Inc (GLUE) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 27.69% per share during the next fiscal year.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Trading Performance Indicators
Take a look at Monte Rosa Therapeutics Inc’s (GLUE) current performance indicators. Last quarter, stock had a quick ratio of 6.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 53.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.24, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.83 in one year’s time.
Technical Analysis of Monte Rosa Therapeutics Inc (GLUE)
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) saw its 5-day average volume 1.37 million, a positive change from its year-to-date volume of 0.24 million. As of the previous 9 days, the stock’s Stochastic %D was 12.97%. Additionally, its Average True Range was 0.47.
During the past 100 days, Monte Rosa Therapeutics Inc’s (GLUE) raw stochastic average was set at 46.61%, which indicates a significant increase from 4.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.23% in the past 14 days, which was lower than the 96.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.38, while its 200-day Moving Average is $5.35. Nevertheless, the first resistance level for the watch stands at $5.14 in the near term. At $5.29, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.38. If the price goes on to break the first support level at $4.90, it is likely to go to the next support level at $4.81. Assuming the price breaks the second support level, the third support level stands at $4.66.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Key Stats
The company with the Market Capitalisation of 306.85 million has total of 50,512K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -135,350 K annual income. Company’s last quarter sales were recorded 4,700 K and last quarter income was -30,310 K.
